PANTOPRAZOLE SODIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	2C16H14F2N3O4S.2Na.3H2O
Molecular Weight	864.749
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.[Na+].[Na+].COC1=CC=NC(C[S+]([O-])C2=NC3=C([N-]2)C=C(OC(F)F)C=C3)=C1OC.COC4=CC=NC(C[S+]([O-])C5=NC6=C([N-]5)C=C(OC(F)F)C=C6)=C4OC

InChI

InChIKey=VNKNFEINTHUQGZ-UHFFFAOYSA-N

InChI=1S/2C16H14F2N3O4S.2Na.3H2O/c2*1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;;;;/h2*3-7,15H,8H2,1-2H3;;;3*1H2/q2*-1;2*+1;;;

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H15F2N3O4S
Molecular Weight	383.37
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours. Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus for adults and pediatric patients 5 years of age and older caused by gastroesophageal reflux disease. It can be used as a maintenance therapy for long-term use after initial response is obtained, but there have not been any controlled studies about the use of pantoprazole past a duration of 12 months. Pantoprazole may also be used in combination with antibiotics to treat ulcers caused by Helicobacter pylori. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18536934 \| https://www.ncbi.nlm.nih.gov/pubmed/8389196	Inhibitor 8297
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11402494	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis associated with gastroesophageal reflux disease 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000
Zollinger-Ellison syndrome 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781 substrate 1737	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 383 OAT3 642 CYP2C8 911 CYP1A2 1524 CYP2A6 707 CYP2E1 882 P-gp 1461 BCRP 699 CYP2C19 1478 OAT1 599 OATP1B1 788 OATP1B3 706 OCT1 512 OCT2 647 OCT3 150 ALDH1 40 MATE2 263 MATE1 306 OATP2B1 123	CYP2C19 991 P-gp 1537 sulfotransferases 38	CYP1A 56 CYP1A1 108 CYP2C 15

Drug as perpetrator

Target	Modality	Activity
ALDH1 40	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	inconclusive [Activation 22.3872 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19139163/	likely
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6Ilx0Q0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
MATE2 263	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >500 uM]
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	no
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP2C19 1553	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://drug-interactions.medicine.iu.edu/MainTable.aspx \| https://pubmed.ncbi.nlm.nih.gov/21795468/	weak [IC50 93 uM]
P-gp 1650	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.9 uM]
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 2.8 uM]
OCT3 150	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 22.9 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 30.8 uM]
OAT3 644	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.45 uM]
MATE1 308	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	yes [IC50 43.2 uM]
BCRP 773	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16380 \| https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 5.5 uM]
OAT1 603	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 63.21 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15258107/	yes [Ki 6.5 uM]
CYP1A 121	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=21 Page: (Pharm_P7) 21	yes
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/	yes
CYP2C 34	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
MRP2 475	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OCT3 150	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29346&ns=ncit&type=relationship&key=n75796996&b=1&n=0&vse=null Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
P-gp 1537	substrate 3367 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes
sulfotransferases 38	substrate 3367 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=102625707 \| https://pubmed.ncbi.nlm.nih.gov/9165689/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915
ChemicalBook	CB51025809	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51025809
ChemicalBook	CB8129842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8129842
MolPort	MolPort-003-666-752	https://www.molport.com/shop/molecule-link/MolPort-003-666-752
MolPort	MolPort-005-933-577	https://www.molport.com/shop/molecule-link/MolPort-005-933-577
eMolecules	902267	https://www.emolecules.com/cgi-bin/more?vid=902267

PubMed

Title	Date	PubMed
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.	2001	11768559
Lansoprazole: an update of its place in the management of acid-related disorders.	2001	11693467
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.	2001 Aug	11507354
Resolution of Menetrier's disease after Helicobacter pylori eradication therapy.	2001 Aug 24	11589437
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.	2001 Dec	11770010
Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia.	2001 Dec	11736723
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).	2001 Dec 17	11802510
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.	2001 Jul	11474311
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.	2001 Jul	11421879
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.	2001 Jul	11421878
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?	2001 Jul	11421877
[Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma].	2001 Jul-Aug	11475787
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.	2001 May	11430508
Cluster headache without autonomic symptoms?	2001 Nov	11903290
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.	2001 Nov	11692067
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.	2001 Nov	11685025
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.	2001 Nov	11683695
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.	2001 Nov	11683686
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.	2001 Oct	11718254
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.	2001 Oct	11695354
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.	2001 Sep	11552908
[Comparative study of proton pump inhibitors].	2001 Sep 9	11680100
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].	2002	12353402
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	2002	12222994
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].	2002	12043311
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.	2002 Apr	11929403
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.	2002 Aug	12182745
[Proton pump inhibitors: Pantoprazole].	2002 Feb	11979865
Protonix. First i.v. proton pump inhibitor approved.	2002 Feb	11924161
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.	2002 Jan	11743248
Conformational analysis: a new approach by means of chemometrics.	2002 Jan 30	11926199
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.	2002 Jul	12177723
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.	2002 Jul	12152007
Proton pump inhibitors: an update.	2002 Jul 15	12152963
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.	2002 Jul 15	12119060
Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.	2002 Jul-Aug	12143188
Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.	2002 Jul-Aug	12115018
Intravenous proton pump inhibitors in the critical care setting.	2002 Jun	12072664
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.	2002 Jun	12072662
Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.	2002 Jun	12072661
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.	2002 Jun	12072599
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.	2002 Jun 22	12077038
[Correlation of Barrett's esophagus and colonic adenomas].	2002 Jun 9	12132329
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.	2002 Mar	11876710
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.	2002 Mar	11849125
Combination drug therapy for gastroesophageal reflux disease.	2002 May	11978171
Stability of pantoprazole in an extemporaneously compounded oral liquid.	2002 May 15	12040734
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.	2002 Oct	12352294
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.	2002 Oct 21	12381251
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.	2002 Sep	12395996

Patents

Sample Use Guides

In Vivo Use Guide

Oral use: Short-Term Treatment of Erosive Esophagitis Associated With GERD: 40 mg Once daily for up to 8 weeks; Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: 40 mg Twice daily IV: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days

Route of Administration: Other

In Vitro Use Guide

To determine "ex vivo" gastric mucosa gastric acid secretion, pantoprazole (as DMSO solution diluted with serosal fluid) was added to membrane mucosa liquid in the bath tube. Pantoprazole final concentration in serosal fluidwas 5 mkM, incubation time -- 2.5h. Pantoprazole mediated gastric acid secretion inhibition is 24.3% at 5mkM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:48:36 GMT 2023` Edited by `admin` on `Fri Dec 15 18:48:36 GMT 2023`
Record UNII	6871619Q5X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PANTOPRAZOLE SODIUM

Official Name

English

PANTOPRAZOLE SODIUM [MART.]

Common Name

English

5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole, sodium salt, sesquihydrate

Common Name

English

PANTOPRAZOLE (AS SODIUM)

Common Name

English

PANTOPRAZOLE SODIUM [VANDF]

Common Name

English

PANTOPRAZOLE SODIUM [USAN]

Common Name

English

PANTOPRAZOLE SODIUM [USP-RS]

Common Name

English

SODIUM 5-(DIFLUOROMETHOXY)-2-((RS)-((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)BENZIMIDAZOL-1-IDE SESQUIHYDRATE

Common Name

English

PROTONIX

Brand Name

English

SOMAC CONTROL

Brand Name

English

PANTOPRAZOLE SODIUM [ORANGE BOOK]

Common Name

English

Pantoprazole sodium sesquihydrate [WHO-DD]

Common Name

English

PANTOPRAZOLE SODIUM HYDRATE

Common Name

English

PANTOPRAZOLE SODIUM [USP IMPURITY]

Common Name

English

1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (2:3)

Common Name

English

CONTROLOC CONTROL

Brand Name

English

PANTOPRAZOLE SODIUM SESQUIHYDRATE [EP MONOGRAPH]

Common Name

English

PANTOPRAZOLE SODIUM [USP MONOGRAPH]

Common Name

English

PANTOPRAZOLE SODIUM HYDRATE [JAN]

Common Name

English

1H-BENZIMIDAZOLE, 6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (2:2:3)

Systematic Name

English

PANTOZOL CONTROL

Brand Name

English

PANTOPRAZOLE SODIUM SESQUIHYDRATE

Common Name

English

PANTOPRAZOLE (AS SODIUM SESQUIHYDRATE)

Common Name

English

PANTOLOC CONTROL

Brand Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

PANTOLOC CONTROL (AUTHORIZED: GASTROESOPHAGEAL REFLUX)